BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eigen Receives Two Grant Awards from U.S. Department of Health and Human Services


4/22/2011 8:46:55 AM

GRASS VALLEY, Calif., April 22, 2011 /PRNewswire/ -- Eigen is the proud recipient of two grant awards from the Qualifying Therapeutic Discovery Project (QTDP) funded by the U.S. Department of Health & Human Services. QTDP tax credits are provided under section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). Eigen received the maximum $244,000 award for each grant awarded in October, 2010, and January, 2011. These credits support biomedical research by small companies which may have major impact on the diagnosis and treatment of significant diseases.

With this grant, Eigen continues to rapidly move forward, bringing breakthrough medical imaging products to market. Additionally, the QTDP grants have enabled the company to hire additional local talent to support growing company needs.

Artemis, Eigen's flagship product, uses proprietary, next-generation imaging technology and provides solutionsnot previously availablewhich enhance urologists' existing 2D ultrasound imagery with full color 3D modeling used for "smart" prostate biopsies.

"Artemis has provided a great leap forward in the diagnosis of prostate cancer," says Brian Burr, Eigen CEO. "It has added precision along with the ability to guide, track, and record exact biopsy locations. Artemis lets doctors re-biopsy the same location accurately in a subsequent biopsy. This has previously not been an option. Artemis technology provides high quality, real-time information that enhances how prostate cancer is managed. Better patient information equals better patient decisions."

Eigen is also breaking into the prostate cancer therapy market. The company hopes to receive future support from such programs as the QTDP, allowing it to continue providing quality imaging devices to medical professionals worldwide.

About Eigen

Eigen is a world leader in the development of innovative imaging devices and technology that lets healthcare professionals improve their ability to visualize, diagnose and determine appropriate treatment pathways in over 4,000 hospitals worldwide. Located at 13366 Grass Valley Avenue, Grass Valley, CA 95945, visit Eigen at www.eigen.com.

SOURCE Eigen


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->